Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cardiovascular Systems stock

Own Cardiovascular Systems stock in just a few minutes.

Cardiovascular Systems, Inc is a medical devices business based in the US. Cardiovascular Systems shares (CSII) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiovascular Systems employs 779 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cardiovascular Systems

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CSII – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cardiovascular Systems share price

Use our graph to track the performance of CSII stocks over time.

Cardiovascular Systems shares at a glance

Information last updated 2021-04-30.
52-week range$27.70 - $48.28
50-day moving average $39.17
200-day moving average $39.95
Wall St. target price$47.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.01

Buy Cardiovascular Systems shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cardiovascular Systems stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Cardiovascular Systems under- or over-valued?

Valuing Cardiovascular Systems stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cardiovascular Systems's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cardiovascular Systems's PEG ratio

Cardiovascular Systems's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 177.27. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cardiovascular Systems's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Cardiovascular Systems's EBITDA

Cardiovascular Systems's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 million.

The EBITDA is a measure of a Cardiovascular Systems's overall financial performance and is widely used to measure a its profitability.

Cardiovascular Systems financials

Revenue TTM $228.4 million
Gross profit TTM $187.8 million
Return on assets TTM -3.19%
Return on equity TTM -9.68%
Profit margin -8.84%
Book value $6.81
Market capitalisation $1.6 billion

TTM: trailing 12 months

Shorting Cardiovascular Systems shares

There are currently 1.1 million Cardiovascular Systems shares held short by investors – that's known as Cardiovascular Systems's "short interest". This figure is 0.2% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting Cardiovascular Systems shares can be evaluated.

Cardiovascular Systems's "short interest ratio" (SIR)

Cardiovascular Systems's "short interest ratio" (SIR) is the quantity of Cardiovascular Systems shares currently shorted divided by the average quantity of Cardiovascular Systems shares traded daily (recently around 201974.60035524). Cardiovascular Systems's SIR currently stands at 5.63. In other words for every 100,000 Cardiovascular Systems shares traded daily on the market, roughly 5630 shares are currently held short.

However Cardiovascular Systems's short interest can also be evaluated against the total number of Cardiovascular Systems shares, or, against the total number of tradable Cardiovascular Systems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cardiovascular Systems's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cardiovascular Systems shares in existence, roughly 30 shares are currently held short) or 0.0411% of the tradable shares (for every 100,000 tradable Cardiovascular Systems shares, roughly 41 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cardiovascular Systems.

Find out more about how you can short Cardiovascular Systems stock.

Cardiovascular Systems share dividends

We're not expecting Cardiovascular Systems to pay a dividend over the next 12 months.

Have Cardiovascular Systems's shares ever split?

Cardiovascular Systems's shares were split on a 1:10 basis on 25 February 2009. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiovascular Systems shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cardiovascular Systems shares which in turn could have impacted Cardiovascular Systems's share price.

Cardiovascular Systems share price volatility

Over the last 12 months, Cardiovascular Systems's shares have ranged in value from as little as $27.7 up to $48.28. A popular way to gauge a stock's volatility is its "beta".

CSII.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiovascular Systems's is 0.818. This would suggest that Cardiovascular Systems's shares are less volatile than average (for this exchange).

Cardiovascular Systems overview

Cardiovascular Systems, Inc. , a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site